ALNY FY 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.7B+65.2% YoY

Gross Profit

$3.0B81.8% margin

Operating Income

$502M13.5% margin

Net Income

$314M8.4% margin

EPS (Diluted)

$2.33

Cash Flow

Operating Cash Flow

$524M

Free Cash Flow

$465M

Stock-Based Comp.

$348M

Balance Sheet

Total Assets

$5.0B

Total Liabilities

$4.2B

Stockholders' Equity

$789M

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$2.2B	+65.2%
Gross Profit	$3.0B	$1.9B	+57.8%
Operating Income	$502M	-$177M	+383.6%
Net Income	$314M	-$278M	+212.8%